antihypertensive agents

Summary

Summary: Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Top Publications

  1. ncbi The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report
    Aram V Chobanian
    Department of Medicine, Boston University School of Medicine, Boston, Mass, USA
    JAMA 289:2560-72. 2003
  2. ncbi Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
    Aram V Chobanian
    Boston University School of Medicine, Boston, Mass, USA
    Hypertension 42:1206-52. 2003
  3. ncbi US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008
    Brent M Egan
    Department of Medicine, Medical University of South Carolina, 135 Rutledge Ave, 1230 RT, Charleston, SC 29425, USA
    JAMA 303:2043-50. 2010
  4. ncbi 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension
    Judith A Whitworth
    John Curtin School of Medical Research, Australian National University, Canberra, Australia
    J Hypertens 21:1983-92. 2003
  5. ncbi Updated clinical classification of pulmonary hypertension
    Gerald Simonneau
    Centre National de Référence des Maladies Vasculaires Pulmonaires, Universite Paris Sud, Hopital Antoine Beclere, Clamart, France
    J Am Coll Cardiol 54:S43-54. 2009
  6. pmc Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies
    M R Law
    Centre for Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ
    BMJ 338:b1665. 2009
  7. ncbi Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study
    Bryan Williams
    Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
    Circulation 113:1213-25. 2006
  8. ncbi Predictors of long-term progression in the early manifest glaucoma trial
    M Cristina Leske
    Department of Preventive Medicine, Stony Brook University Medical Center, Stony Brook, New York 11794 8036, USA
    Ophthalmology 114:1965-72. 2007
  9. ncbi Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study
    Henry Krum
    Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic, Australia
    Lancet 373:1275-81. 2009
  10. ncbi Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    B M Brenner
    Renal Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 345:861-9. 2001

Detail Information

Publications350 found, 100 shown here

  1. ncbi The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report
    Aram V Chobanian
    Department of Medicine, Boston University School of Medicine, Boston, Mass, USA
    JAMA 289:2560-72. 2003
    ..Empathy builds trust and is a potent motivator. Finally, in presenting these guidelines, the committee recognizes that the responsible physician's judgment remains paramount...
  2. ncbi Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
    Aram V Chobanian
    Boston University School of Medicine, Boston, Mass, USA
    Hypertension 42:1206-52. 2003
    ..Positive experiences, trust in the clinician, and empathy improve patient motivation and satisfaction. This report serves as a guide, and the committee continues to recognize that the responsible physician's judgment remains paramount...
  3. ncbi US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008
    Brent M Egan
    Department of Medicine, Medical University of South Carolina, 135 Rutledge Ave, 1230 RT, Charleston, SC 29425, USA
    JAMA 303:2043-50. 2010
    ..Hypertension is a major risk factor for cardiovascular disease and treatment and control of hypertension reduces risk. The Healthy People 2010 goal was to achieve blood pressure (BP) control in 50% of the US population...
  4. ncbi 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension
    Judith A Whitworth
    John Curtin School of Medical Research, Australian National University, Canberra, Australia
    J Hypertens 21:1983-92. 2003
    ....
  5. ncbi Updated clinical classification of pulmonary hypertension
    Gerald Simonneau
    Centre National de Référence des Maladies Vasculaires Pulmonaires, Universite Paris Sud, Hopital Antoine Beclere, Clamart, France
    J Am Coll Cardiol 54:S43-54. 2009
    ..Finally, it was decided to place pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis in a separate group, distinct from but very close to Group 1 (now called Group 1'). Thus, Group 1 of PAH is now more homogeneous...
  6. pmc Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies
    M R Law
    Centre for Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ
    BMJ 338:b1665. 2009
    ..To determine the quantitative efficacy of different classes of blood pressure lowering drugs in preventing coronary heart disease (CHD) and stroke, and who should receive treatment...
  7. ncbi Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study
    Bryan Williams
    Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
    Circulation 113:1213-25. 2006
    ....
  8. ncbi Predictors of long-term progression in the early manifest glaucoma trial
    M Cristina Leske
    Department of Preventive Medicine, Stony Brook University Medical Center, Stony Brook, New York 11794 8036, USA
    Ophthalmology 114:1965-72. 2007
    ..To determine progression factors at the end of the Early Manifest Glaucoma Trial (EMGT) based on all EMGT patients and evaluate separately patients with higher and lower baseline intraocular pressure (IOP; median split)...
  9. ncbi Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study
    Henry Krum
    Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic, Australia
    Lancet 373:1275-81. 2009
    ....
  10. ncbi Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    B M Brenner
    Renal Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 345:861-9. 2001
    ..We assessed the role of the angiotensin-II-receptor antagonist losartan in patients with type 2 diabetes and nephropathy...
  11. ncbi Treatment of hypertension in patients 80 years of age or older
    Nigel S Beckett
    Care of the Elderly, Division of Medicine, Imperial College London, United Kingdom
    N Engl J Med 358:1887-98. 2008
    ..Whether the treatment of patients with hypertension who are 80 years of age or older is beneficial is unclear. It has been suggested that antihypertensive therapy may reduce the risk of stroke, despite possibly increasing the risk of death...
  12. ncbi Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries
    Marta Pereira
    Department of Hygiene and Epidemiology, Cardiovascular R and D Unit, Universityof Porto Medical School, Porto, Portugal
    J Hypertens 27:963-75. 2009
    ..The prevalence, awareness, treatment and control of hypertension in developing countries are coming closer to those in developed countries...
  13. pmc Predictive validity of a medication adherence measure in an outpatient setting
    Donald E Morisky
    Department of Community Health Sciences, UCLA School of Public Health, Los Angeles, CA 90095 1772, USA
    J Clin Hypertens (Greenwich) 10:348-54. 2008
    ....
  14. pmc Updated evidence-based treatment algorithm in pulmonary arterial hypertension
    Robyn J Barst
    Columbia University, New York, New York 10583, USA
    J Am Coll Cardiol 54:S78-84. 2009
    ..Atrial septostomy and lung transplantation are indicated for refractory patients or where medical treatment is unavailable...
  15. ncbi Hypertension prevalence, awareness, treatment, and control in mozambique: urban/rural gap during epidemiological transition
    Albertino Damasceno
    Eduardo Mondlane University, Maputo, Mozambique
    Hypertension 54:77-83. 2009
    ..The urban/rural differences across sexes support a trend toward smaller differences, emphasizing the need for strategies to improve prevention, correct diagnosis, and access to effective treatment...
  16. pmc Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008
    Brent M Egan
    Department of Medicine, Medical University of South Carolina, 135 Rutledge Ave, 1230 RT, Charleston, SC 29425, USA
    Circulation 124:1046-58. 2011
    ..Despite progress, many hypertensive patients remain uncontrolled. Defining characteristics of uncontrolled hypertensives may facilitate efforts to improve blood pressure control...
  17. ncbi Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000
    Ihab Hajjar
    Division of Geriatrics, Department of Medicine, Palmetto Health Richland, University of South Carolina, Columbia, USA
    JAMA 290:199-206. 2003
    ..Prior analyses of National Health and Nutrition Examination Survey (NHANES) data through 1991 have suggested that hypertension prevalence is declining, but more recent self-reported rates of hypertension suggest that the rate is increasing...
  18. ncbi The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma
    Michael A Kass
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    Arch Ophthalmol 120:701-13; discussion 829-30. 2002
    ..There is no consensus on the efficacy of medical treatment in delaying or preventing the onset of POAG in individuals with elevated IOP. Therefore, we designed a randomized clinical trial, the Ocular Hypertension Treatment Study...
  19. ncbi Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial
    Gerald Simonneau
    Division of Pulmonary and Critical Care Medicine, Antoine Beclere Hospital, Clamart, Paris Sud University, Clamart, France
    Am J Respir Crit Care Med 165:800-4. 2002
    ..We conclude that chronic subcutaneous infusion of treprostinil is an effective treatment with an acceptable safety profile in patients with pulmonary arterial hypertension...
  20. ncbi Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV
    B Williams
    Department of Cardiovascular Sciences, Clinical Sciences Building, Leicester Royal Infirmary, University of Leicester, UK
    J Hum Hypertens 18:139-85. 2004
  21. ncbi Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
    E J Lewis
    Department of Medicine, Rush-Presbyterian-St Luke's Medical Center, Chicago, IL 60612, USA
    N Engl J Med 345:851-60. 2001
    ..CONCLUSIONS: The angiotensin-II-receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type 2 diabetes. This protection is independent of the reduction in blood pressure it causes...
  22. ncbi Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension
    William B White
    Division of Hypertension and Clinical Pharmacology, Calhoun Cardiology Center, University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT 06030 3940, USA
    Hypertension 57:413-20. 2011
    ..Azilsartan medoxomil could provide higher rates of hypertension control within the ARB class...
  23. ncbi Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
    Peter Gaede
    Steno Diabetes Center, Copenhagen, Denmark
    N Engl J Med 348:383-93. 2003
    ....
  24. ncbi Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
    Salim Yusuf
    McMaster Clinic, Room 252, Hamilton General Hospital, 237 Barton Street East, ON, L8L 2X2, Hamilton, Canada
    Lancet 362:777-81. 2003
    ..We investigated the effect of addition of an angiotensin-receptor blocker to current treatments...
  25. ncbi Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis
    William J Elliott
    Department of Preventive Medicine, Rush Medical College of Rush University at Rush University Medical Center, Chicago, IL 60612, USA
    Lancet 369:201-7. 2007
    ..We therefore undertook a network meta-analysis, which accounts for both direct and indirect comparisons to assess the effects of antihypertensive agents on incident diabetes.
  26. ncbi The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study
    Francoise Forette
    Department of Geriatrics, Hopital Broca, CHU Cochin, University of Paris V, 54 56 Rue Pascal, 75013 Paris, France
    Arch Intern Med 162:2046-52. 2002
    ..After the double-blind, placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial ended in February 1997, randomized patients were offered active study medication for a further period of observation...
  27. ncbi Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study
    Kazuomi Kario
    Department of Cardiology, Jichi Medical School, Tochigi, Japan
    Circulation 107:1401-6. 2003
    ..Cardiovascular events occur most frequently in the morning hours. We prospectively studied the association between the morning blood pressure (BP) surge and stroke in elderly hypertensives...
  28. ncbi Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators
    J A Staessen
    Department of Molecular and Cardiovascular Research, University of Louvain, Leuven, Belgium
    JAMA 282:539-46. 1999
    ..The clinical use of ambulatory blood pressure (BP) monitoring requires further validation in prospective outcome studies...
  29. ncbi Hypertension management 2011: optimal combination therapy
    Peter S Sever
    International Centre for Circulatory Health, Imperial College London, 59 North Wharf Road, London W2 1LA, UK
    Eur Heart J 32:2499-506. 2011
    ..What then is the next step if blood pressure is not a goal after the patient has been treated with monotherapy for a few weeks? Should you uptitrate, substitute or combine?..
  30. ncbi The age-dependent relation of blood pressure to cognitive function and dementia
    Chengxuan Qiu
    Aging Research Centre, Division of Geriatric Epidemiology and Medicine, Department of Neurotec, Karolinska Institute and Stockholm Gerontology Research Centre, Stockholm, Sweden
    Lancet Neurol 4:487-99. 2005
    ....
  31. pmc Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease
    Rhonda M Cooper-Dehoff
    Department of Pharmacotherapy and Translational Research and Division of Cardiovascular Medicine, College of Pharmacy, University of Florida, 1600 SW Archer Rd, PO Box 100486, Gainesville, FL 32610 0486, USA
    JAMA 304:61-8. 2010
    ..Hypertension guidelines advocate treating systolic blood pressure (BP) to less than 130 mm Hg for patients with diabetes mellitus; however, data are lacking for the growing population who also have coronary artery disease (CAD)...
  32. pmc Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994
    S Capewell
    University of Glasgow, Department of Public Health, 2 Lilybank Gardens, Glasgow G12 8RZ, UK
    Heart 81:380-6. 1999
    ..To estimate the fall in coronary heart disease (CHD) mortality in Scotland attributable to medical and surgical treatments, and risk factor changes, between 1975 and 1994...
  33. pmc Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades
    Finlay A McAlister
    University of Alberta, Edmonton, Alberta
    CMAJ 183:1007-13. 2011
    ..This study was done to examine the trends in the prevalence of hypertension and in control rates in Canada between 1992 and 2009...
  34. pmc Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999-2008
    Andreas Kuznik
    Pfizer Inc, New York, New York, USA
    Cardiovasc Diabetol 10:31. 2011
    ..This analysis assessed recent trends in the utilization of lipid-lowering and BP-lowering agents, as well as LDL-C and BP goal attainment, in the U.S. adult diabetic population...
  35. ncbi Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials
    Sripal Bangalore
    New York University School of Medicine, New York, NY, USA
    Lancet Oncol 12:65-82. 2011
    ..We assessed the association between antihypertensive drugs and cancer risk in a comprehensive analysis of data from randomised clinical trials...
  36. ncbi Health-related quality of life in patients with pulmonary arterial hypertension
    Shirin Shafazand
    The George Washington University, Washington Hospital Center, Washington, DC, USA
    Chest 126:1452-9. 2004
    ..This study describes HRQOL in a cohort of patients with PAH...
  37. pmc A strategy to reduce cardiovascular disease by more than 80%
    N J Wald
    Department of Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, Barts and The London, Queen Mary s School of Medicine and Dentistry, University of London, London EC1M 6BQ
    BMJ 326:1419. 2003
    ..The strategy was to simultaneously reduce four cardiovascular risk factors (low density lipoprotein cholesterol, blood pressure, serum homocysteine, and platelet function) regardless of pretreatment levels...
  38. ncbi Blood pressure control in Italy: results of recent surveys on hypertension
    Massimo Volpe
    Division of Cardiology, II Faculty of Medicine, University of Rome La Sapienza, Sant Andrea Hospital, Rome, Italy
    J Hypertens 25:1491-8. 2007
    ..Blood pressure (BP) control is reported to be poor in hypertensive patients worldwide...
  39. ncbi Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    Scott M Grundy
    Circulation 110:227-39. 2004
    ..Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy...
  40. ncbi Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis
    Tazeen H Jafar
    Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    Ann Intern Med 139:244-52. 2003
    ..Angiotensin-converting enzyme (ACE) inhibitors reduce blood pressure and urine protein excretion and slow the progression of chronic kidney disease...
  41. ncbi Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis
    Ajay K Gupta
    International Centre for Circulatory Health, Imperial College London, London, United Kingdom
    Hypertension 55:399-407. 2010
    Two or more antihypertensive agents are increasingly used to control blood pressure (BP) in hypertensive patients...
  42. ncbi Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial
    Richard J McManus
    Primary Care Clinical Sciences, University of Birmingham and National Institute for Health Research NIHR National School for Primary Care Research, Birmingham, UK
    Lancet 376:163-72. 2010
    ..This study assessed whether self-management by people with poorly controlled hypertension resulted in better blood pressure control compared with usual care...
  43. ncbi Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Preventi
    Clive Rosendorff
    Veterans Health Administration, USA
    Circulation 115:2761-88. 2007
  44. ncbi Hypertension and cerebral white matter lesions in a prospective cohort study
    F E de Leeuw
    Department of Epidemiology and Biostatistics, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Brain 125:765-72. 2002
    ..Adequate treatment of hypertension may therefore prevent white matter lesions and the associated cognitive decline...
  45. ncbi Hypertension in South African adults: results from the Demographic and Health Survey, 1998
    K Steyn
    Chronic Diseases of Lifestyle Unit, Medical Research Council MRC, Tygerberg, South Africa
    J Hypertens 19:1717-25. 2001
    ..To determine the prevalence and treatment status of hypertension in South Africa...
  46. ncbi Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial
    Jackson T Wright
    Case Western Reserve University, Department of Medicine, University Hospitals of Cleveland and the Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH 44106 5014, USA
    JAMA 288:2421-31. 2002
    ..Hypertension is a leading cause of end-stage renal disease (ESRD) in the United States, with no known treatment to prevent progressive declines leading to ESRD...
  47. ncbi Prevalence of resistant hypertension in the United States, 2003-2008
    Stephen D Persell
    Division of General Internal Medicine, Feinberg School of Medicine, Northwestern University, 750 N Lake Shore Dr, 10th Floor, Chicago, IL 60611, USA
    Hypertension 57:1076-80. 2011
    ..Among those classified here as resistant, inadequate diuretic therapy may be a modifiable therapeutic target. Cardiovascular diseases, diabetes mellitus, obesity, and renal dysfunction were all common in this population...
  48. ncbi EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries
    Kornelia Kotseva
    Department of Cardiovascular Medicine, National Heart and Lung Institute, Imperial College London, London, UK
    Eur J Cardiovasc Prev Rehabil 17:530-40. 2010
    ..To determine whether the 2003 Joint European Societies' guidelines on cardiovascular disease prevention in people at high cardiovascular risk have been followed in general practice...
  49. ncbi A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly
    Lindon M H Wing
    School of Medicine, Flinders University, Adelaide, Australia
    N Engl J Med 348:583-92. 2003
    ..We compared the outcomes in older subjects with hypertension who were treated with angiotensin-converting-enzyme (ACE) inhibitors with the outcomes in those treated with diuretic agents...
  50. ncbi Control of blood pressure as measured at home and office, and comparison with physicians' assessment of control among treated hypertensive patients in Japan: First Report of the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) study
    Takayoshi Ohkubo
    Department of Planning for Drug Development and Clinical Evaluation, Tohoku University Graduate School of Pharmaceutical Science and Medicine, Sendai, Japan
    Hypertens Res 27:755-63. 2004
    ..Our findings suggest that an important reason why home and office BP values are not adequately controlled is that physicians approve relatively higher BP levels under treatment, even among middle-aged patients...
  51. pmc The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy
    Daniel G Hackam
    Department of Medicine and Epidemiology, Division of Clinical Pharmacology and Clinical Neurological Sciences, University of Western Ontario, London, Ontario
    Can J Cardiol 26:249-58. 2010
    ..To update the evidence-based recommendations for the prevention and treatment of hypertension in adults for 2010...
  52. ncbi The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
    H H Parving
    Steno Diabetes Center, Copenhagen, Denmark
    N Engl J Med 345:870-8. 2001
    ..02). CONCLUSIONS: Irbesartan is renoprotective independently of its blood-pressure-lowering effect in patients with type 2 diabetes and microalbuminuria...
  53. ncbi Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial
    Vallerie V McLaughlin
    University of Michigan Health System, CVC Cardiovascular Medicine, Ann Arbor, Michigan 48109 5853, USA
    J Am Coll Cardiol 55:1915-22. 2010
    ..This study assessed the efficacy and safety of inhaled treprostinil in pulmonary arterial hypertension (PAH) patients receiving therapy with either bosentan or sildenafil...
  54. ncbi Cardiovascular protection and blood pressure reduction: a meta-analysis
    J A Staessen
    Studiecoördinatiecentrum, Hypertensie en Cardiovasculaire Revalidatie Eenheid, Departement Moleculair en Cardiovasculair Onderzoek, Katholieke Universiteit Leuven, Leuven, Belgium
    Lancet 358:1305-15. 2001
    ..We aimed to investigate whether pharmacological properties of antihypertensive drugs or reduction of systolic pressure accounted for cardiovascular outcome in hypertensive or high-risk patients...
  55. ncbi Effect of antihypertensive agents on blood pressure variability: the Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study
    Yi Zhang
    Centre de Diagnostic et de Thérapeutique, Hotel Dieu, 1, Place du Parvis Notre Dame, 75181 Paris Cedex 04, France
    Hypertension 58:155-60. 2011
    To investigate the effect of different antihypertensive agents on blood pressure (BP) variability (BPV) and the underlying mechanism, we analyzed the ambulatory BP monitoring data of 577 patients before and after 3-month antihypertensive ..
  56. ncbi Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients
    Kim Thanh Ong
    Hopitaux de Paris, Hopital Europeen Georges Pompidou, France bINSERM U970, France
    J Hypertens 29:1034-42. 2011
    ..We aimed to determine whether the artery stiffness can be improved because of antihypertensive treatments independently of blood pressure lowering...
  57. ncbi Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice
    Giovanni Corrao
    Department of Statistics, Unit of Biostatistics and Epidemiology, University of Milano Bicocca, Milan, Italy
    Hypertension 58:566-72. 2011
    ..In daily life practice, a combination of antihypertensive drugs is associated with a great reduction of CV risk. The indication for using combination of blood pressure drugs should be broadened...
  58. ncbi The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma
    Mae O Gordon
    OHTS Coordinating Center, Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, Box 8203, 660 South Euclid, St Louis, MO 63110, USA
    Arch Ophthalmol 120:714-20; discussion 829-30. 2002
    ....
  59. ncbi Essential hypertension
    Franz H Messerli
    Division of Cardiology, St Luke s Roosevelt Hospital Center, Columbia University, College of Physicians and Surgeons, New York, NY 10019, USA
    Lancet 370:591-603. 2007
    ..Despite the availability of effective and safe antihypertensive drugs, hypertension and its concomitant risk factors remain uncontrolled in most patients...
  60. ncbi Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials
    Fiona Turnbull
    Blood Pressure Lowering Treatment Trialists Collaboration, The George Institute for International Health, University of Sydney, PO Box 576, Newtown, Sydney, New South Wales 2042, Australia
    Lancet 362:1527-35. 2003
    ....
  61. ncbi Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring
    Domenic Sica
    Section of Clinical Pharmacology and Hypertension, Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 13:467-72. 2011
    ..These findings suggest that AZL-M could provide higher rates of hypertension control compared with other ARBs in the class...
  62. ncbi Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke
    Peter M Rothwell
    Stroke Prevention Research Unit, University Department of Clinical Neurology, John Radcliffe Hospital, Oxford, UK
    Lancet Neurol 9:469-80. 2010
    ..We aimed to investigate whether the effects of these drugs on variability in blood pressure might explain these disparities in effect on stroke risk...
  63. ncbi Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women
    Maria G Modena
    Institute of Cardiology, Department of Internal Medicine, Azienda Ospedaliera Universitaria, Policlinico, University of Modena, Modena, Italy
    J Am Coll Cardiol 40:505-10. 2002
    ....
  64. pmc Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories
    Bernard Vrijens
    Pharmionic Research Center, Rue des Cyclistes Frontière 24, 4600 Visé, Belgium
    BMJ 336:1114-7. 2008
    ..To describe characteristics of dosing history in patients prescribed a once a day antihypertensive medication...
  65. ncbi Epidemiology of uncontrolled hypertension in the United States
    Thomas J Wang
    Framingham Heart Study, Framingham, MA 01702, USA
    Circulation 112:1651-62. 2005
  66. pmc Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study
    E Imai
    Department of Nephrology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa Ku, Nagoya, Aichi 466 8550, Japan
    Diabetologia 54:2978-86. 2011
    ..The renal and cardiovascular protective effects of angiotensin receptor blocker (ARB) remain controversial in type 2 diabetic patients treated with a contemporary regimen including an angiotensin converting enzyme inhibitor (ACEI)...
  67. ncbi Antihypertensive peptides from food proteins: a review
    Daniel Martínez-Maqueda
    Institute of Food Science Research CIAL, CSIC UAM Nicolás Cabrera, 9, Campus de la Universidad Autonoma de Madrid, 28049, Madrid, Spain
    Food Funct 3:350-61. 2012
    ..Other aspects, such as the mechanism of action and bioavailability of these peptides which play a key role in their antihypertensive effects are also summarized in this review...
  68. ncbi Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis
    Angela M Thompson
    Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, 1440 Canal St, New Orleans, LA 70112 2715, USA
    JAMA 305:913-22. 2011
    ..Cardiovascular disease (CVD) risk increases beginning at systolic blood pressure levels of 115 mm Hg. Use of antihypertensive medications among patients with a history of CVD or diabetes and without hypertension has been debated...
  69. ncbi Efficacy and safety of benazepril for advanced chronic renal insufficiency
    Fan Fan Hou
    Renal Division, Nanfang Hospital, Southern Medical University, Guangzhou, China
    N Engl J Med 354:131-40. 2006
    ..0 mg per deciliter or less). We assessed the efficacy and safety of benazepril in patients without diabetes who had advanced renal insufficiency...
  70. ncbi The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study
    Mark J Sarnak
    Division of Nephrology, Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    Ann Intern Med 142:342-51. 2005
    ..Hypertension is a risk factor for progression of chronic kidney disease. The optimal blood pressure to slow progression is unknown...
  71. ncbi Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOS
    Henry Krum
    Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University Alfred Hospital, Melbourne VIC 3004, Australia
    Eur J Heart Fail 13:107-14. 2011
    ..Perspective The ATMOSPHERE study will definitively determine the role of a DRI strategy additional to or as an alternative to conventional RAAS blockade in patients with chronic systolic HF...
  72. ncbi Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement
    John M Flack
    Department of Internal Medicine, Wayne State University, Detroit, Mich, USA
    Hypertension 56:780-800. 2010
    ....
  73. ncbi Renal and vascular protective effects of cilnidipine in patients with essential hypertension
    Satoshi Morimoto
    Department of Internal Medicine, Ohmihachiman City Hospital, Japan
    J Hypertens 25:2178-83. 2007
    ..This study compares the effects on renal and vascular endothelial functions and arterial stiffness of monotherapy regimens of amlodipine, an L-type calcium antagonist, and cilnidipine, in patients with essential hypertension...
  74. ncbi Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis
    Rajiv Agarwal
    Indiana University School of Medicine and Richard L Roudebush Veterans Administration Medical Center, Indianapolis, Ind 46202, USA
    Hypertension 57:29-38. 2011
    ..Hypertension control with home BP monitoring can be enhanced further when accompanied by plans to monitor and treat elevated BP such as through telemonitoring...
  75. ncbi Antihypertensive treatment based on blood pressure measurement at home or in the physician's office: a randomized controlled trial
    Jan A Staessen
    Study Coordinating Centre, Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium
    JAMA 291:955-64. 2004
    ..Self-measurement of blood pressure is increasingly used in clinical practice, but how it affects the treatment of hypertension requires further study...
  76. ncbi Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial
    Victor F Tapson
    Division of Pulmonary and Critical Care Medicine, Room 351 Bell Building, Duke University Medical Center, Durham, NC 27710, USA
    Chest 129:683-8. 2006
    ..With continuous IV treprostinil having potential advantages over both of the above therapies, we investigated the safety and efficacy of this regimen in patients with PAH...
  77. ncbi Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis
    Juan P Casas
    Centre for Clinical Pharmacology, Department of Medicine, BHF Laboratories at University College London, London, UK
    Lancet 366:2026-33. 2005
    ..Guidelines specify that these are the drugs of choice for the treatment of hypertension in patients with renal disease. We sought to determine to what extent this consensus is supported by the available evidence...
  78. ncbi When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal
    Alberto Zanchetti
    Istituto Auxologico Italiano, Italy
    J Hypertens 27:923-34. 2009
    ..Nonetheless, they can be accepted as prudent statements, as antihypertensive agents are very well tolerated and lowering systolic blood pressure below 130 mmHg appears well tolerated...
  79. ncbi Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study
    Suzanne Oparil
    University of Alabama at Birmingham, 35294 0007, USA
    Clin Ther 32:1252-69. 2010
    Patients with hypertension may require a combination of > or =2 antihypertensive agents to achieve blood pressure (BP) control.
  80. ncbi Feasibility of treating prehypertension with an angiotensin-receptor blocker
    Stevo Julius
    University of Michigan, Department of Internal Medicine, Division of Cardiovascular Medicine, Ann Arbor, MI 48106, USA
    N Engl J Med 354:1685-97. 2006
    ..Prehypertension is considered a precursor of stage 1 hypertension and a predictor of excessive cardiovascular risk. We investigated whether pharmacologic treatment of prehypertension prevents or postpones stage 1 hypertension...
  81. ncbi Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
    Bjorn Dahlof
    Sahlgrenska University Hospital Ostra, Gothenburg, Swede
    Lancet 359:995-1003. 2002
    ..We aimed to establish whether selective blocking of angiotensin II improves LVH beyond reducing blood pressure and, consequently, reduces cardiovascular morbidity and death...
  82. pmc Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials
    F Turnbull
    George Institute for International Health, University of Sydney, PO Box M201, Sydney, NSW 2050, Australia
    BMJ 336:1121-3. 2008
    ..To quantify the relative risk reductions achieved with different regimens to lower blood pressure in younger and older adults...
  83. ncbi Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-B
    Bjorn Dahlof
    Department of Medicine, Sahlgrenska University Hospital Ostra, SE 416 85 Goteborg, Sweden
    Lancet 366:895-906. 2005
    ..Our aim, therefore, was to compare the effect on non-fatal myocardial infarction and fatal CHD of combinations of atenolol with a thiazide versus amlodipine with perindopril...
  84. ncbi 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension
    Giuseppe Mancia
    University of Milano Bicocca, Ospedale San Gerardo, Milan, Italy
    J Hypertens 25:1751-62. 2007
  85. ncbi Bosentan therapy for pulmonary arterial hypertension
    Lewis J Rubin
    Division of Pulmonary and Critical Care Medicine, University of California at San Diego, La Jolla 92037 1330, USA
    N Engl J Med 346:896-903. 2002
    ..The present trial investigated the effect of bosentan on exercise capacity in a larger number of patients and compared two doses...
  86. ncbi Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES)
    Joachim Schrader
    Department of Internal Medicine, St Josefs Hospital, Cloppenburg, Germany
    Stroke 36:1218-26. 2005
    ..In hypertensive stroke patients, for the same level of blood pressure control, eprosartan will be more effective than nitrendipine in reducing cerebrovascular and cardiovascular morbidity and mortality...
  87. pmc Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study
    Julie A Johnson
    University of Florida College of Pharmacy and Center for Pharmacogenomics, Gainesville, USA
    Am Heart J 157:442-9. 2009
    ..Selection of antihypertensive therapy is often empiric, and use of genetic information to guide drug therapy selection holds future promise...
  88. ncbi Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models
    Keiji Kusumoto
    Metabolic Disease Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, Osaka, Japan
    Eur J Pharmacol 669:84-93. 2011
    ..These results suggest that azilsartan medoxomil is a potent angiotensin II receptor blocker that has an attractive pharmacological profile as an antihypertensive agent...
  89. ncbi Ambulatory blood-pressure monitoring
    Thomas G Pickering
    Behavioral Cardiovascular Health and Hypertension Program, Department of Medicine, Columbia Presbyterian Medical Center, New York, USA
    N Engl J Med 354:2368-74. 2006
  90. ncbi A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide
    Matthew R Weir
    University of Maryland School of Medicine, Baltimore, MD, USA
    J Clin Hypertens (Greenwich) 13:404-12. 2011
    ....
  91. ncbi Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: results from the EUROASPIRE III survey
    Christof Prugger
    Institute of Epidemiology and Social Medicine, University of Munster, Munster, Germany
    J Hypertens 29:1641-8. 2011
    ..Blood pressure management is a key issue among patients with coronary heart disease (CHD). The present study aimed to identify particular patient groups that may need to be specifically targeted in secondary prevention of CHD...
  92. ncbi Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial
    Henry R Black
    Rush Medical College of Rush University, Chicago, IL 60612, USA
    JAMA 289:2073-82. 2003
    ..Hypertensive patients are often given a calcium antagonist to reduce cardiovascular disease risk, but the benefit compared with other drug classes is controversial...
  93. ncbi Etiology and management of postpartum hypertension-preeclampsia
    Baha M Sibai
    Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, University of Cincinnati, Cincinnati, Ohio, USA
    Am J Obstet Gynecol 206:470-5. 2012
    ..The objective of this review is to increase awareness and to provide a stepwise approach toward the diagnosis and management of women with persistent and/or new-onset hypertension-preeclampsia postpartum period...
  94. ncbi Impact of home blood pressure telemonitoring and blood pressure control: a meta-analysis of randomized controlled studies
    Stefano Omboni
    Italian Institute of Telemedicine, Varese, Italy
    Am J Hypertens 24:989-98. 2011
    ..To summarize the effectiveness of home blood pressure telemonitoring on blood pressure control from randomized, controlled studies...
  95. ncbi Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective
    Mardi Gomberg-Maitland
    University of Chicago Medical Center, Chicago, Illinois 60611, USA
    J Am Coll Cardiol 57:1053-61. 2011
    ..Although definitive evidence will require randomized and properly controlled long-term trials, the current evidence supports the long-term use of these drugs for the treatment of patients with PAH...
  96. ncbi Antihypertensive medication adherence and subsequent healthcare utilization and costs
    Donald G Pittman
    Medco Health Solutions, Inc, Franklin Lakes, NJ 07417, USA
    Am J Manag Care 16:568-76. 2010
    ..To evaluate the relationship between adherence to antihypertensive medications (AHMs) and subsequent hospitalizations, emergency department (ED) visits, and costs of care...
  97. ncbi Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension
    Keith C Ferdinand
    Emory University, Atlanta, GA 30349, USA
    J Am Soc Hypertens 5:102-13. 2011
    ..2% and 40.2%, respectively. Combination aliskiren/amlodipine therapy was effective in treating these high-risk patients but inclusion of HCTZ provided greater antihypertensive efficacy. Both treatments were similarly well tolerated...
  98. ncbi Clinical practice. Nephropathy in patients with type 2 diabetes
    Giuseppe Remuzzi
    Unit of Nephrology, Ospedali Riuniti di Bergamo, Italy
    N Engl J Med 346:1145-51. 2002
  99. ncbi Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension
    Almira Chabi
    Merck Sharp and Dohme Corp, PO Box 1000, North Wales, PA 19454 1099, USA
    Am J Ophthalmol 153:1187-96. 2012
    ..To compare the efficacy and safety of tafluprost, a preservative-free (PF) prostaglandin analogue, with PF timolol in patients with open-angle glaucoma or ocular hypertension...
  100. ncbi Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke
    Peter M Rothwell
    Stroke Prevention Research Unit, Department of Clinical Neurology, University of Oxford, Oxford, UK
    Lancet 377:1681-92. 2011
    ..We review the main medical treatments that should be considered for most patients with transient ischaemic attack or ischaemic stroke in the acute phase and the long term, and draw attention to recent developments...
  101. ncbi Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT)
    Mihai Gheorghiade
    Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, 645 N Michigan Avenue, Suite 1006, Chicago, IL 60611, USA
    Eur J Heart Fail 13:100-6. 2011
    ..The aim of the Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) study is to evaluate the effect of aliskiren on cardiovascular death and HF in AHFS patients...

Research Grants64

  1. Hypertension Pharmacogenetics
    Julie Johnson; Fiscal Year: 2006
    ..The proposed studies should add substantial new information about antihypertensive pharmacogenetics, and could influence how antihypertensive medications are prescribed in the future. ..
  2. Discovery metabolite profiling of the prolyl peptidases
    Alan Saghatelian; Fiscal Year: 2009
    ..Furthermore, the application of DMP to peptidases will demonstrate the generality of this approach for the future characterization of medically relevant enzymes and signaling pathways. ..
  3. Novel Therapy for Preeclampsia
    James W Larrick; Fiscal Year: 2012
    ..Digibind was effective for PE in a clinical trial. We will develop a novel human monoclonal antibody with higher specificity than Digibind for MBG. This innovative therapeutic humAb will be the first effective treatment of PE. ..
  4. A rational approach to liver toxicity monitoring in methotrexate users
    Gabriela Schmajuk; Fiscal Year: 2013
    ..This mentored career development award will provide the skills, mentorship, and experience necessary to propel her to independence. ..
  5. Markers of Renal Damage in Renovascular Hypertension
    Juan C Romero; Fiscal Year: 2011
    ..Elucidation of all these issues will have enormous clinical repercussion in the diagnosis, follow up, and treatment of renovascular hypertension. ..
  6. 2011 Mechanisms of Membrane Transport Gordon Research Conference
    Nancy Carrasco; Fiscal Year: 2011
    ....
  7. Blood Pressure Regulation: Novel Roles for the Kidney
    Pablo A Ortiz; Fiscal Year: 2013
    ..Thus it will accelerate acquisition of knowledge of the novel mechanisms by which the kidney regulates blood pressure, and may provide new targets for anti-hypertensive drugs. ..
  8. Comparative safety &effectiveness of antihypertensive medications in pregnancy
    BRIAN THOMAS BATEMAN; Fiscal Year: 2013
    ..This combination of intensive research, mentoring, and formal education will provide the necessary background for me to become a successful, independent researcher in obstetric pharmacoepidemiology. ..
  9. Novel ex-vivo Immunoadsorption Therapy to Treat Preeclampsia
    Woo Joo; Fiscal Year: 2013
    ..The total market for Aggamin's therapeutic product to treat severe early-onset PE cases in the US is estimated at $0.5-1.5 billion. ..
  10. Combined Computational and Wet Lab Screening for Drugs Tested via OATs
    Sanjay K Nigam; Fiscal Year: 2010
    ..The goal is to identify highly specific substrates for the nasally expressed organic anion transporters, Oat1 and Oat6, thereby allowing for efficient intranasal delivery and transport of drugs to the CNS. ..
  11. Heat Waves, Medication Use, and Adverse Health Outcomes Among Older Adults
    SOKO SETOGUCHI-IWATA; Fiscal Year: 2013
    ....
  12. Regulation of AT1R-signaling and pathology in vessels through microRNA
    Sadashiva S Karnik; Fiscal Year: 2013
    ..There is potential relevance for this knowledge base in understanding normal functioning aorta, vasculature in brain, kidney and heart, as well as the pathology of heart failure, atherosclerosis and aortic aneurysm. ..
  13. Longitudinal Impact of Antihypertensive Polypharmacy on Geriatric Syndromes
    Joseph T Hanlon; Fiscal Year: 2012
    ..e., blood pressure control), and morbidity and mortality (i.e., hospitalization and death due to cardiovascular and cerebrovascular disease). Such studies are consistent with NIA's priority comparative effectiveness research area. ..
  14. Genetic Discovery and Application in a Clinical Setting Continuing a Partnership
    Eric B Larson; Fiscal Year: 2013
    ..Methods to use these results in clinical care will be guided by focus groups of patients and caregivers in the patient-centered Group Health system. ..
  15. Mechanisms of the Relaxation Response in Elderly Hypertensives
    Jeffery A Dusek; Fiscal Year: 2010
    ..controlling systolic blood pressure pharmacologically and the prevalence of side effects produced by many antihypertensive agents, identification of non-pharmacologic approaches to decrease systolic blood pressure in older Systolic ..
  16. Blood Pressure Regulation by OAT3
    Volker Vallon; Fiscal Year: 2013
    ..We will also identify selective OAT3- blocking substances and explore their ability to reduce blood pressure - such substances could potentially be useful in the treatment of patients with hypertension. ..
  17. Pharmacogenomic Evaluation of Antihypertensive Responses
    Julie A Johnson; Fiscal Year: 2013
    ....
  18. Genetic Epidemiology of Treatment Resistant Hypertension in African Americans
    CHRISTOPHER O apos BRIAN PHILLIPS; Fiscal Year: 2013
    ..in the natural history of treatment resistant hypertension (defined as BP>140/90 mmHg despite >3 antihypertensive agents at optimum dose including a diuretic) in African Americans...
  19. Metabolomics Network for Drug Response Phenotype
    RIMA F KADDURAH DAOUK; Fiscal Year: 2010
    ..Such knowledge can lead to more effective and personalized therapies. ..
  20. Peptide mimics of BMP7 for treatment of renal fibrosis and diabetic nephropathy
    William J Dower; Fiscal Year: 2012
    ....
  21. Androgens raise venous and arterial adrenergic tone.
    Douglas S Martin; Fiscal Year: 2010
    ..A better understanding the factors that control arterial and venous tone in hypertension may lead to design antihypertensive drugs with fewer adverse effects ..
  22. Aging and The Renin-Angiotensin System in Elderly Hypertensive Individuals
    Ihab M Hajjar; Fiscal Year: 2011
    ..It will also allow us to combine expertise from various fields to increase our understanding of the underlying mechanism by which cardiovascular disease affects aging. ..
  23. Biomechanical Factors in Congenital Vascular Disease
    JESSICA WAGENSEIL; Fiscal Year: 2013
    ..These studies will be important for identifying the mechanical and genetic pathways that lead to arterial narrowing in diseases such as COA and SVAS and will test preventative treatments. ..
  24. Hypertension, angiotensin receptor blockers, cognition: effects and mechanisms
    Ihab M Hajjar; Fiscal Year: 2013
    ..This project will also improve our understanding of the possible mechanisms of action of this class of antihypertensives. ..
  25. Determinants of Medication Adherence in HIV-Infected Adults with Hypertension
    Jeffrey J Weiss; Fiscal Year: 2011
    ....
  26. Long-term Antihypertensive Therapy by Delivery of the BK Channel Gene to VSMCs
    Nancy J Rusch; Fiscal Year: 2012
    ..abstract_text> ..
  27. Functional evaluation of GWAS loci for cardiovascular intermediate phenotypes
    Calum A Macrae; Fiscal Year: 2010
    ..The zebrafish can model many human diseases, and in this application a multidisciplinary team will integrate insights from zebrafish biology and the Framingham Heart Study to explore the genetics of major cardiovascular diseases. ..
  28. AT1R-regulated nuclear functions of Gb2
    Sadashiva S Karnik; Fiscal Year: 2012
    ..A clear understanding of novel transcription regulatory mechanisms is important to improve the therapeutic application of ARBs. These proposed studies will advance our knowledge of AT1R biology. ..
  29. Effect of treating one disease on other diseases and health outcomes in elders
    Mary E Tinetti; Fiscal Year: 2012
    ..Our ultimate goal is to develop a method for determining the optimal treatments for older adults with multiple conditions that maximizes benefit and minimizes harm within the outcome domain(s) of highest priority for each patient. ..
  30. Impact of Medicaid Policy on cardiovascular drug use and clinical outcomes
    Michael A Fischer; Fiscal Year: 2010
    ....
  31. Pharmaconeuropathology of Brain Aging and Dementia
    Joshua A Sonnen; Fiscal Year: 2013
    ..abstract_text> ..
  32. Clinical Centers for the HALT-Polycystic Kidney Disease Trials (U01)
    Ronald D Perrone; Fiscal Year: 2013
    ..Other antihypertensive agents are added as needed to meet the BP goals...
  33. Secondary Prevention of Subcortical Stroke Prevention Genetic Substudy
    Alan R Shuldiner; Fiscal Year: 2013
    ..We will also conduct a study to identify genetic variants that increase the risk for subcortical stroke. ..
  34. Anti-hypertensive drugs that prevent Alzheimer's disease beta-amyloid pathology a
    Giulio Maria Pasinetti; Fiscal Year: 2010
    ....
  35. Visit-to-visit variability of blood pressure and CVD and renal outcomes
    Paul Muntner; Fiscal Year: 2013
    ..If VVV is confirmed as a risk factor for these outcomes, it may transform how BP measurements are used in patient management (e.g., identifying high risk patients and guiding choice of antihypertensive agents).
  36. Regulation of Drug/Xenobiotic Transporter OAT by Ubiquitination
    Guofeng You; Fiscal Year: 2013
    ....
  37. Mail-Order Pharmacy Use and Medication Adherence Among Older Adults with Diabetes
    Obidiugwu Kenrik Duru; Fiscal Year: 2013
    ..Duru with the training and skills needed to become an independent investigator, conducting intervention research that results in tangible improvements in the health of vulnerable older adults. ..
  38. Variation in Antihypertensive Prescribing Patterns in Children
    ESTHER YOUNGAE YOON; Fiscal Year: 2013
    ....
  39. Comparative Effectiveness of ACE Inhibitors for African Americans
    GBENGA GODWIN OGEDEGBE; Fiscal Year: 2011
    ....
  40. MASS SPECTROMETER SYSTEM AND ACCESSORIES
    ALAN NIES; Fiscal Year: 1990
    ..For this proposal, the University has committed funds for renovation of space and maintenance of the requested instrument in order to ensure its optimal utilization...
  41. PROSTAGLANDINS AND LOCAL CONTROL OF THE CIRCULATION
    ALAN NIES; Fiscal Year: 1990
    ....
  42. REVERSAL OF MYOCARDIAL HYPERTROPHY IN HYPERTENSION
    Subha Sen; Fiscal Year: 2002
    ..On identifying the derangement, we will determine if appropriate treatment corrects the changes and if such directed alteration in myocardial collagen formation improves the compromised function of the hypertrophied heart. ..
  43. Enhancing Fulfillment Data in Community Practices for Clinical Care and Research
    Michael G Kahn; Fiscal Year: 2012
    ....
  44. Translating Dietary Trials into the Community
    Alain Bertoni; Fiscal Year: 2009
    ..will be aged 21+ and have pre-HTN or HTN with blood pressure between 120-150/80-95 mmHg on 0,1 or 2 antihypertensive agents, and will be AA residents of Eastern Winston-Salem (a lower-income area whose population is 65 percent AA)..
  45. EFFECTS OF DIFFERENTIAL COST SHARING IN THE ELDERLY
    Stephen Soumerai; Fiscal Year: 1999
    ..abstract_text> ..
  46. PEDIATRIC PHARMACOLOGY RESEARCH UNIT
    Jeffrey Blumer; Fiscal Year: 2009
    ..of ongoing PPRU activities we have developed two print symposia, one dealing with the evaluation of antihypertensive agents in children and the other dealing with the treatment of sleep disorders in children, designed to set the ..
  47. Pirfenidone: Anti-Scarring Drug for Diabetic Nephropathy
    Kumar Sharma; Fiscal Year: 2005
    ....
  48. ACE inhibitor and prevention of diabetic retinopathy
    Jinzhong Zhang; Fiscal Year: 2004
    ..We believe that agents having this effect can be characterized and improved, offering an additional pharmacologic means to inhibit the development and progression of diabetic retinopathy. ..
  49. SODIUM-POTASSIUM BLOOD PRESSURE TRIAL IN CHILDREN
    Alan Sinaiko; Fiscal Year: 1991
    ....
  50. TOXICOLOGICAL ASPECTS OF HEMOPROTEIN REGULATION
    Yoichi Osawa; Fiscal Year: 2004
    ..These findings may be important as NO plays a key role in penile erection and antihypertensive agents as well as cigarette smoking are known to cause impotence...
  51. APPROACHES TO NATRIURETIC AND ANTIHYPERTENSIVE AGENTS
    William Wechter; Fiscal Year: 2001
    ..The successful accomplishment of this research, namely the synthesis of new eukaliuretic natriuretic-antihypertensive agents and the identification of the natriuretic receptor, would be of great significance to the treatment of ..
  52. Low-Renin Hypertension in African Americans
    John Pratt; Fiscal Year: 2003
    ..with many failing to achieve a normal blood pressure despite the availability of a wide variety of antihypertensive agents. The low-renin state is consistent with increased retention of sodium...
  53. PROTEIN KINASE INHIBITORS
    David Hangauer; Fiscal Year: 1993
    ..This anticipation is precedented by literature reports showing selectivities on the order of 10-5,000 fold among isozymes of particular enzymes with substrate-derived inhibitors...
  54. MECHANISM OF CENTRALLY-ACTING ANTIHYPERTENSIVE DRUGS
    Jerry Buccafusco; Fiscal Year: 1991
    ..Finally, several clonidene-like antihypertensive agents will be examined for central inhibition of cholinergic function in this spinal model system, and a new ..
  55. ALPHA2-ADRENERGIC RECEPTOR SUBTYPES IN THE CNS
    Kevin Lynch; Fiscal Year: 1993
    ..Finally, our results might help address an important issue in receptor biology, i.e. why are there multiple, apparently closely related, receptor subtypes for each of the cationic amines?..
  56. ADRENERGIC VASOREGULATORY INTERACTIONS IN HYPERTENSION
    Richard Weinshilboum; Fiscal Year: 1980
    ..Inhibitors of MAO have been used clinically as antihypertensive agents. PST plays an important role in the metabolism of catecholamines in the central nervous system and in the ..
  57. PHARMACOLOGIC FACTORS & SEXUALITY IN AGING HYPERTENSION
    Brian Hoffman; Fiscal Year: 1992
    ..Methodology, humans: Psychometric, psychophysiological and psychophysical (sensory) testing; nocturnal penile tumescence measurements and prospective data keeping of components of sexual behavior...
  58. VASODILATOR KINETICS & DYNAMICS IN
    Ho Leung Fung; Fiscal Year: 1993
    ..of patients' drug therapy: will certain diseases or other alterations of physiologic status modify not only the pharmacokinetics but also (and perhaps predominantly) the pharmacodynamics (concentration-effect relationship) of a drug?..
  59. ANGIOTENSIN II EFFECTS ON CARDIAC FIBROSIS
    Peter Brecher; Fiscal Year: 1999
    ....
  60. BRAIN AND CARDIAC ANGIOTENSIN II IN HYPERTENSION
    KATHLEEN BERECEK; Fiscal Year: 2003
    ..Ang II and/or its receptors which is passed on to offspring of treated rats and/or due to accumulation of antihypertensive agents such as bradykinin (BK), Ang (1-7) or nitric oxide (NO) which are passed on to offspring of treated rats...
  61. MOLECULAR MECHANISMS OF DRUG/XENOBIOTIC ELIMINATION
    Guofeng You; Fiscal Year: 2009
    ....
  62. Angiotensin II Receptor Blockade and Chronic Rejection
    Bryan Becker; Fiscal Year: 2003
    ....
  63. IMPROVING UTILIATION OF ISCHEMIC STROKE RESEARCH
    Catherine Borbas; Fiscal Year: 2002
    ..At the control hospitals, we will provide a minimalist intervention involving informal opinion leaders but not hospital leadership. ..
  64. Mechanisms of Pb-induced Hypertension: Role of Altered Calcium Homeostasis
    WILLIAM ATCHISON; Fiscal Year: 2007
    ..Sensitivity of Pb -exposed rats to two groups of commonly used antihypertensive agents including Ca channel blockers will be tested to determine if sensitivity to these important ..